Description

Ondansetron Orally Disintegrating Tablets

Ondansetron Orally Disintegrating Tablets USP / BP / IP (4 mg / 8 mg)

Fast-Dissolving Selective Serotonin 5-HT3 Receptor Antagonist Antiemetic

Healthy Life Pharma Private Limited, alongside our specialized global export and marketing division Healthy Inc, is a leading Indian manufacturer, CDMO services provider, and wholesale supplier of advanced gastroenterology, oncology supportive care, and surgical therapeutics. We manufacture an internationally standardized, high-precision selection of Ondansetron Orally Disintegrating Tablets (ODT) within our state-of-the-art, WHO–GMP certified solid dosage cleanroom facilities.

Serving as a premium, fast-acting clinical asset to halt severe emetic reflexes without requiring water intake, this specialized drug delivery system represents a high-velocity strategic export to oncology treatment networks, surgical hospital groups, national healthcare procurement pipelines, and international digital B2B pharmaceutical marketplaces across the CIS region, Sub-Saharan Africa, LATAM, and South-East Asia.

Product Overview

This formulation operates as a “Peripheral & Central Serotonin Signal Interrupter.” It ensures immediate antiemetic stabilization by physically blocking the specific nerve channels that trigger the brain’s vomiting center when the gastrointestinal tract faces acute chemotherapeutic, surgical, or cellular stress.

• Mechanism 1 (Selective 5-HT3 Receptor Antagonism): Ondansetron is an exceptionally potent, highly competitive antagonist at Serotonin Type 3 ($\text{5-HT}_{3}$) receptors. It executes this blockade with high specificity, displaying zero cross-reactivity with dopamine, histamine, or muscarinic receptors.

• Mechanism 2 (Peripheral Vagal Veto): Cancer chemotherapeutics, radiation, and surgical manipulation physically trigger enterochromaffin cells in the small intestine mucosa to release massive amounts of serotonin. This serotonin normally binds to vagal afferent nerve $\text{5-HT}_{3}$ receptors, sending severe emetic signals to the brain. Ondansetron physically blocks these peripheral nerve receptors, stopping the signal at the source.

• Mechanism 3 (Central Chemoreceptor Suppression): Concurrently, the molecule targets and blocks central $\text{5-HT}_{3}$ receptors situated inside the Chemoreceptor Trigger Zone (CTZ) in the Area Postrema of the brainstem. This dual peripheral and central action completely neutralizes the vomiting reflex cascade, preventing both acute nausea and active physical retching.

Product Composition & Available Formats

We supply Ondansetron ODT in the two primary compendial configurations required to support initial introductory pediatric dosing up to high-potency surgical and oncological maintenance regimens.

Technical & Logistics Specifications

• HS Code: 3004.90.99 (Medicaments acting on the alimentary tract / Antiemetics / Serotonin Antagonists)

• CAS Number: 99614-02-5 (Ondansetron Base) / 103639-04-9 (Ondansetron Hydrochloride Dihydrate)

• Dosage Form: Orally Disintegrating Tablet (ODT) (Engineered to dissolve completely on the tongue within 10 to 15 seconds without requiring water or swallowing efforts)

• Packaging Configurations: 10 Tablets per Blister Strip packed exclusively in high-barrier Alu-Alu (Cold-Form Foil) with Peel-Off Backing Laminates. ODT matrices are physically delicate and highly hygroscopic; our specialized tropicalized foil packaging isolates every individual tablet from environmental moisture while preventing mechanical breakage during transit, guaranteeing a full 36-month shelf life in hot, humid Zone IVb export environments.

Advanced ODT Matrix Engineering & Quality Attributes

                 [ MICRONIZED ONDANSETRON API ]
                               │
                               ▼
           [ HYDROPHILIC POLYMER & SACCHARIDE BLENDING SUITE ]
                               │ (Specialized micro-crystalline mannitol infrastructure)
                               ▼
            [ ULTRA-LOW PREVALENCE DIRECT COMPRESSION ]
                               │ (Calibrated to allow immediate water-wicking ingress)
         ┌─────────────────────┴─────────────────────┐
         ▼                                           ▼
 [ RAPID LIQUID DEPOSIT WICK ]             [ COHERENT TASTE-MASKING SHIELD ]
 Complete Dissolution in <15 Seconds        Flawless Suppression of Bitter API

• Advanced Rapid-Dispersion Matrix Technology: Our ODT formulations utilize a specialized, highly porous Micro-Crystalline Mannitol and Crospovidone Wicking Scaffold. Upon contact with minimal quantities of saliva on the tongue, the hydrophilic matrix rapidly pulls fluid into the tablet core via capillary action, dissolving the structural bonds within 15 seconds to create a smooth, easy-to-swallow suspension.

• Micro-Encapsulated Taste-Masking Systems: Raw Ondansetron active chemical has an intensely bitter and metallic flavor profile that can provoke severe retching in a highly nauseous patient. Our processing lines deploy a Multi-Stage Taste-Masking Matrix utilizing Pharma-Grade Sucralose and Micronized Sweet Mint Flavor Crystals, physically isolating the bitter active cores on the tongue to guarantee high patient acceptance.

• Low-Force Compression Architecture: To ensure that the highly porous ODT matrix remains physically stable during high-velocity packaging operations while maintaining instant-dissolve capabilities, we utilize advanced rotary presses calibrated to precise, low-tonnage compression parameters paired with online mechanical friability verifiers.

Primary Indications

• Oncology & Radiotherapy: Prophylaxis and immediate management of acute and delayed Chemotherapy-Induced Nausea and Vomiting (CINV) associated with highly and moderately emetogenic anticancer drug cycles, and Radiation-Induced Nausea and Vomiting (RINV).

• Post-Operative Recovery: Prevention and treatment of Post-Operative Nausea and Vomiting (PONV) following inpatient or outpatient surgical procedures.

• Emergency Medicine Adjuvant: Rapid control of severe emesis associated with acute gastroenteritis or cyclical vomiting syndromes in adult and pediatric networks.

Usage Instructions

• The Peel-Pack Administration Protocol: Instruct clinical and patient networks that the ODT tablet must not be pushed physically through the blister foil, as this mechanical force can fracture the porous core. Instead, with dry hands, the backing laminate must be physically peeled back from the blister pocket, and the tablet gently placed directly on top of the tongue.

• The Water-Free Swallowing Mechanics: Once positioned on the tongue, the tablet will dissolve completely within seconds in normal saliva. The patient can then swallow the dissolved matrix naturally without needing water or liquid down-flushing.

• The Pre-Treatment Chemotherapy Window: For maximum clinical efficacy against chemotherapy-induced emesis, the initial 8 mg ODT dose must be administered physically 30 to 60 minutes prior to the initiation of the anti-cancer infusion, setting up an immediate chemical blockade at the receptor sites before serotonin dumping occurs.

Safety Warning: HIGH-POTENCY ULTRA-SELECTIVE SEROTONIN ANTAGONIST ANTIEMETIC. For Medical and Specialist Supervision Only. The QT-Interval Prolongation Caution: Ondansetron chemically alters myocardial conduction pathways in a dose-dependent manner; use with extreme caution in patients presenting with congenital Long QT Syndrome, pre-existing cardiac arrhythmias, hypokalemia, or hypomagnesemia. The Serotonin Syndrome Overload Risk: Co-administration with other serotonergic agents (such as SSRIs or SNRIs) carries a rare but severe chemical risk of precipitating Serotonin Syndrome. Monitor for symptoms of autonomic instability, tremors, and hyperreflexia. Contraindications: Absolute contraindications in patients concurrently using Apomorphine Hydrochloride (due to reports of profound hypotension and loss of consciousness), or individuals presenting with documented hypersensitivity to ondansetron or related 5-HT3 receptor antagonist structures.

Global CDMO Services & Wholesale Supply Chain

Healthy Life Pharma Private Limited and Healthy Inc provide comprehensive, internationally validated Third-Party Contract Manufacturing (CDMO Services) and bulk private-label export supply for the entire Ondansetron ODT portfolio. Because this molecule faces zero controlled-substance licensing hurdles, our high-capacity lines can rapidly manufacture, release, and ship multi-container institutional shipping loads. We handle all mandatory regulatory documentation (WHO-GMP Certificate, Certificates of Pharmaceutical Product – COPP, Certificates of Analysis – COA, Zone IVb Stability Testing Matrix Sheets, and Complete CTD Format Dossier sets) for seamless entry registration.

Commercial & Bulk Procurement Inquiries:

• Corporate Head Office: Mumbai, Maharashtra, India

• Primary Manufacturing Base: Boisar, Maharashtra, India

• WhatsApp / Direct Call: +91 7710003340

• Corporate Email: info@healthyinc.co.in